RxDoctor Payments Data

Nicholas Defilippis, MD

Internal Medicine · Union, NJNPI 1518962257

Payments from drug & device makers

$8,761in general payments, 2019–2025

Across 559 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$972
  • Lilly USA, LLC$724
  • AbbVie$592
  • Johnson & Johnson$562
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,69799%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,761 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$586,861
Medicare patients
410
Services billed
16,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol103$105,896
OzempicSemaglutide63$104,855
JardianceEmpagliflozin65$100,185
XareltoRivaroxaban33$40,369
RybelsusSemaglutide24$39,649
EliquisApixaban25$34,551
TrulicityDulaglutide20$29,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$28,748
EntrestoSacubitril/Valsartan13$12,330
Atorvastatin Calcium771$10,563
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide160$8,252
Rosuvastatin Calcium276$5,134
Breo ElliptaFluticasone/Vilanterol12$4,783
Levothyroxine Sodium340$4,625
Ezetimibe102$4,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,010$144,50387 claims
AstraZenecaFarxiga$1,721$105,896103 claims
Boehringer IngelheimJardiance$489$100,18565 claims
Johnson & JohnsonXarelto$562$40,36933 claims
PfizerEliquis$117$34,55125 claims
GSKTrelegy Ellipta, Breo Ellipta$972$33,53244 claims
Lilly USA, LLCTrulicity$724$29,33520 claims
NovartisEntresto$215$12,33013 claims
AbbVieSynthroid$592$2,53152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →